Search

Your search keyword '"Cappuzzo, F"' showing total 992 results
Start Over Author "Cappuzzo, F"
992 results on '"Cappuzzo, F"'

2. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

Author

Reale, M.L., Passiglia, F., Cappuzzo, F., Minuti, G., Occhipinti, M., Bulotta, A., Delmonte, A., Sini, C., Galetta, D., Roca, E., Pelizzari, G., Cortinovis, D., Gariazzo, E., Pilotto, S., Citarella, F., Bria, E., Muscolino, P., Pozzessere, D., Carta, A., Pignataro, D., Calvetti, L., Leone, F., Banini, M., Di Micco, C., Baldini, E., Favaretto, A., Malapelle, U., Novello, S., Pasello, G., and Tiseo, M.

Published
2024
Full Text
View/download PDF

3. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Author

Passaro, A., Wang, J., Wang, Y., Lee, S.-H., Melosky, B., Shih, J.-Y., Azuma, K., Juan-Vidal, O., Cobo, M., Felip, E., Girard, N., Cortot, A.B., Califano, R., Cappuzzo, F., Owen, S., Popat, S., Tan, J.-L., Salinas, J., Tomasini, P., Gentzler, R.D., William, W.N., Jr., Reckamp, K.L., Takahashi, T., Ganguly, S., Kowalski, D.M., Bearz, A., MacKean, M., Barala, P., Bourla, A.B., Girvin, A., Greger, J., Millington, D., Withelder, M., Xie, J., Sun, T., Shah, S., Diorio, B., Knoblauch, R.E., Bauml, J.M., Campelo, R.G., and Cho, B.C.

Published
2024
Full Text
View/download PDF

4. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R., Garcia Campelo, R., Remon, J., Costantini, D., and Vasseur, B.

Published
2023
Full Text
View/download PDF

6. Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma

Author

Scalera, S., Ricciuti, B., Mazzotta, M., Calonaci, N., Alessi, J.V., Cipriani, L., Bon, G., Messina, B., Lamberti, G., Di Federico, A., Pecci, F., Milite, S., Krasniqi, E., Barba, M., Vici, P., Vecchione, A., De Nicola, F., Ciuffreda, L., Goeman, F., Fanciulli, M., Buglioni, S., Pescarmona, E., Sharma, B., Felt, K.D., Lindsay, J., Rodig, S.J., De Maria, R., Caravagna, G., Cappuzzo, F., Ciliberto, G., Awad, M.M., and Maugeri-Saccà, M.

Published
2023
Full Text
View/download PDF

8. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

Author

Putora, P.M., Fischer, G.F., Früh, M., Califano, R., Faivre-Finn, C., Van Houtte, P., McDonald, F., Nestle, U., Dziadziuszko, R., Le Pechoux, C., Ramella, S., Belderbos, J., Slotman, B.J., Troost, E.G.C., Peeters, S., Widder, J., Pöttgen, C., Reck, M., Blackhall, F., Cappuzzo, F., Besse, B., Novello, S., Garrido, P., Felip, E., O'Brien, M., Paz Ares, L., de Marinis, F., Westeel, V., and De Ruysscher, D.

Published
2020
Full Text
View/download PDF

9. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study

Author

Gobbini, E., Chiari, R., Pizzutillo, P., Bordi, P., Ghilardi, L., Pilotto, S., Osman, G., Cappuzzo, F., Cecere, F., Riccardi, F., Scotti, V., Martelli, O., Borra, G., Maiello, E., Rossi, A., Graziano, P., Gregorc, V., Casartelli, C., Sergi, C., Del Conte, A., Delmonte, A., Bareggi, C., Cortinovis, D., Rizzo, P., Tabbò, F., Rossi, G., Bria, E., Galetta, D., Tiseo, M., Di Maio, M., and Novello, S.

Published
2020
Full Text
View/download PDF

11. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., Vici P., Di Lisa, F, Krasniqi, E, Pizzuti, L, Barba, M, Cannita, K, De Giorgi, U, Borella, F, Foglietta, J, Cariello, A, Ferro, A, Picardo, E, Mitidieri, M, Sini, V, Stani, S, Tonini, G, Santini, D, La Verde, N, Gambaro, A, Grassadonia, A, Tinari, N, Garrone, O, Sarobba, G, Livi, L, Meattini, I, D'Auria, G, Vergati, M, Gamucci, T, Pistelli, M, Berardi, R, Risi, E, Giotta, F, Lorusso, V, Rinaldi, L, Artale, S, Cazzaniga, M, Zustovich, F, Cappuzzo, F, Landi, L, Torrisi, R, Scagnoli, S, Botticelli, A, Michelotti, A, Fratini, B, Saltarelli, R, Paris, I, Muratore, M, Cassano, A, Gianni, L, Gaspari, V, Veltri, E, Zoratto, F, Fiorio, E, Fabbri, M, Mazzotta, M, Ruggeri, E, Pedersini, R, Valerio, M, Filomeno, L, Minelli, M, Scavina, P, Raffaele, M, Astone, A, De Vita, R, Pozzi, M, Riccardi, F, Greco, F, Moscetti, L, Giordano, M, Maugeri-Sacca, M, Zennaro, A, Botti, C, Pelle, F, Cappelli, S, Cavicchi, F, Vizza, E, Sanguineti, G, Tomao, F, Cortesi, E, Marchetti, P, Tomao, S, Speranza, I, Sperduti, I, Ciliberto, G, Vici, P, Di Lisa F. S., Krasniqi E., Pizzuti L., Barba M., Cannita K., De Giorgi U., Borella F., Foglietta J., Cariello A., Ferro A., Picardo E., Mitidieri M., Sini V., Stani S., Tonini G., Santini D., La Verde N., Gambaro A. R., Grassadonia A., Tinari N., Garrone O., Sarobba G., Livi L., Meattini I., D'Auria G., Vergati M., Gamucci T., Pistelli M., Berardi R., Risi E., Giotta F., Lorusso V., Rinaldi L., Artale S., Cazzaniga M. E., Zustovich F., Cappuzzo F., Landi L., Torrisi R., Scagnoli S., Botticelli A., Michelotti A., Fratini B., Saltarelli R., Paris I., Muratore M., Cassano A., Gianni L., Gaspari V., Veltri E. M., Zoratto F., Fiorio E., Fabbri M. A., Mazzotta M., Ruggeri E. M., Pedersini R., Valerio M. R., Filomeno L., Minelli M., Scavina P., Raffaele M., Astone A., De Vita R., Pozzi M., Riccardi F., Greco F., Moscetti L., Giordano M., Maugeri-Sacca M., Zennaro A., Botti C., Pelle F., Cappelli S., Cavicchi F., Vizza E., Sanguineti G., Tomao F., Cortesi E., Marchetti P., Tomao S., Speranza I., Sperduti I., Ciliberto G., and Vici P.

Abstract

Background: In triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available. Methods: We carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recruited. We primarily focused on treatment tolerability, with toxicity being reported as potential cause of treatment discontinuation. Secondarily, we assessed effectiveness in the overall study population and in a subset having a minimum follow-up of 2 years. Results: Overall, 270 patients were retrospectively identified. The 50.4% of the patients had residual node positive disease, 7.8% and 81.9% had large or G3 residual tumor, respectively, and 80.4% a Ki-67 >20%. Toxicity-related treatment discontinuation was observed only in 10.4% of the patients. In the whole population, at a median follow-up of 15 months, 2-year disease-free survival was 62%, 2 and 3-year overall survival 84.0% and 76.2%, respectively. In 129 patients with a median follow-up of 25 months, 2-year disease-free survival was 43.4%, 2 and 3-year overall survival 78.0% and 70.8%, respectively. Six or more cycles of capecitabine were associated with more favourable outcomes compared with less than six cycles. Conclusion: The CaRe study shows an unexpectedly good tolerance of adjuvant capecitabine in a real-world setting, although effectiveness appears to be lower than that observed in the CREATE-X study. Methodological differences between the two studies impose significant limits to comparability concerning ef

Published
2023

12. EP07.04-06 ALK Rearrangement Is Associated with Early Lymphatic Spread in Resected LUAD with Negative Preoperative Mediastinal Staging

Author

Gallina, F.T., primary, Tajè, R., additional, Cecere, F.L., additional, Melis, E., additional, Bertolaccini, L., additional, Spaggiari, L., additional, de Marinis, F., additional, Cannone, G., additional, Busetto, A., additional, Rea, F., additional, Martucci, N., additional, Mercadante, E., additional, Normanno, N., additional, Mazzoni, F., additional, Bongiolatti, S., additional, Voltolini, L., additional, Sperduti, I., additional, Cappuzzo, F., additional, and Facciolo, F., additional

Published
2023
Full Text
View/download PDF

13. P2.08-01 TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC)

Author

Zhou, C., primary, Levy, B.P., additional, Sands, J., additional, Parakh, S., additional, Sugawara, S., additional, Syrigos, K., additional, Ahn, J.S., additional, Zhao, M., additional, Lin, C.-C., additional, Felip, E., additional, Cappuzzo, F., additional, Reck, M., additional, Yang, J.C.H., additional, Joseph, R., additional, Rawat, S., additional, Xie, J., additional, and Okamoto, I., additional

Published
2023
Full Text
View/download PDF

14. P2.05-02 MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial

Author

Cappuzzo, F., primary, Fusco, F., additional, Bonanno, L., additional, Landi, L., additional, Andrikou, K., additional, Dal Maso, A., additional, Minuti, G., additional, Papi, M., additional, Metro, G., additional, Lye, W.K., additional, Ariyaratne, P., additional, Yu, Y., additional, Lau, W.M., additional, Wang, X., additional, Lucke, J., additional, Görtz, A., additional, Attili, I., additional, Piantedosi, F., additional, Pilotto, S., additional, Gori, S., additional, Rossi, G., additional, Buglioni, S., additional, Giannarelli, D., additional, and Delmonte, A., additional

Published
2023
Full Text
View/download PDF

15. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Author

Passaro, A., primary, Wang, J., additional, Wang, Y., additional, Lee, S.-H., additional, Melosky, B., additional, Shih, J.-Y., additional, Azuma, K., additional, Juan-Vidal, O., additional, Cobo, M., additional, Felip, E., additional, Girard, N., additional, Cortot, A.B., additional, Califano, R., additional, Cappuzzo, F., additional, Owen, S., additional, Popat, S., additional, Tan, J.-L., additional, Salinas, J., additional, Tomasini, P., additional, Gentzler, R.D., additional, William, W.N., additional, Reckamp, K.L., additional, Takahashi, T., additional, Ganguly, S., additional, Kowalski, D.M., additional, Bearz, A., additional, MacKean, M., additional, Barala, P., additional, Bourla, A.B., additional, Girvin, A., additional, Greger, J., additional, Millington, D., additional, Withelder, M., additional, Xie, J., additional, Sun, T., additional, Shah, S., additional, Diorio, B., additional, Knoblauch, R.E., additional, Bauml, J.M., additional, Campelo, R.G., additional, and Cho, B.C., additional

Published
2023
Full Text
View/download PDF

16. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Besse, B., primary, Felip, E., additional, Garcia Campelo, R., additional, Cobo, M., additional, Mascaux, C., additional, Madroszyk, A., additional, Cappuzzo, F., additional, Hilgers, W., additional, Romano, G., additional, Denis, F., additional, Viteri, S., additional, Debieuvre, D., additional, Galetta, D., additional, Baldini, E., additional, Razaq, M., additional, Robinet, G., additional, Maio, M., additional, Delmonte, A., additional, Roch, B., additional, Masson, P., additional, Schuette, W., additional, Zer, A., additional, Remon, J., additional, Costantini, D., additional, Vasseur, B., additional, Dziadziuszko, R., additional, Giaccone, G., additional, Zemanová, M., additional, Besse, B., additional, Bonnet, C., additional, Cadranel, J., additional, Chouaid, C., additional, Cortot, A., additional, Delclaux, B., additional, Duchemann, B., additional, El Kouri, C., additional, Ferrand, F.R., additional, Ginoux, M., additional, Mazieres, J., additional, Molinier, O., additional, Moro-Sibilot, D., additional, Pichon, E., additional, Zalcman, G., additional, Schmidtke-Schrezenmeier, G., additional, Urban, L., additional, Gottfried, M., additional, Nechushtan, H., additional, Peled, N., additional, Wollner, M., additional, Bonanno, L., additional, Bonetti, A., additional, Minotti, V., additional, Rea, A., additional, Tassinari, D., additional, Tonini, G., additional, Karaszewska, B., additional, Szczęsna, A., additional, De Castro, J., additional, Garcia Campelo, M.R., additional, Hernández, A., additional, Moran, T., additional, Provencio, M., additional, Dasgupta, A., additional, Gabrail, N., additional, Harshad, A., additional, Liu, S., additional, Oubre, D., additional, Panikkar, R., additional, and Sanborn, R., additional

Published
2023
Full Text
View/download PDF

17. Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib

Author

Mazza V and Cappuzzo F

Subjects
NSCLC (non-small-cell lung cancer), EGFR (Epidermal Growth Factor Receptor), TKI (Tirosine-Kinase Inhibitors), acquired resistance, T790M, osimertinib., Medicine (General), R5-920, Genetics, QH426-470
Abstract

Valentina Mazza,1 Federico Cappuzzo1,2 1Department of Oncology-Hematology, 2Department of Medical Oncology, AUSL Romagna, Ravenna, Italy Abstract: The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with different clinical characteristics and outcome to EGFR-wild-type patients. In these patients, the treatment of choice as first-line therapy is first- or second-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib, erlotinib, or afatinib. Inevitably, after the initial response, all patients become refractory to these drugs. The most common mechanism of acquired resistance to EGFR-TKIs is the development of a second mutation in exon 20 of EGFR (T790M). Osimertinib is a third-generation EGFR-TKI designed for overcoming T790M-mediated resistance. Based on the results of efficacy and tolerability of Phase II and Phase III studies, osimertinib has been approved for treatment of advanced EGFRT790M+ mutation NSCLC following progression on a prior EGFR-TKI. Occurrence of acquired resistance to osimertinib represents an urgent need for additional strategies including combination with other agents, such as other targeted therapies or checkpoint inhibitors, or development of new and more potent compounds. Keywords: EGFR-mutant non-small-cell Lung cancer, acquired resistance, T790M mutation, third generation EGFR-TKI, osimertinib

Published
2017

20. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy

Author

Banna, G, Tiseo, M, Cortinovis, D, Facchinetti, F, Aerts, J, Baldessari, C, Giusti, R, Bria, E, Grossi, F, Berardi, R, Morabito, A, Catino, A, Genova, C, Mazzoni, F, Gelibter, A, Rastelli, F, Macerelli, M, Chiari, R, Gori, S, Mansueto, G, Citarella, F, Cantini, L, Rijavec, E, Bertolini, F, Cappuzzo, F, De Toma, A, Friedlaender, A, Metro, G, Pensieri, M, Porzio, G, Ficorella, C, Pinato, D, Cortellini, A, Addeo, A, Banna GL, Tiseo M, Cortinovis D, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Cappuzzo F, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, Addeo A, Banna, G, Tiseo, M, Cortinovis, D, Facchinetti, F, Aerts, J, Baldessari, C, Giusti, R, Bria, E, Grossi, F, Berardi, R, Morabito, A, Catino, A, Genova, C, Mazzoni, F, Gelibter, A, Rastelli, F, Macerelli, M, Chiari, R, Gori, S, Mansueto, G, Citarella, F, Cantini, L, Rijavec, E, Bertolini, F, Cappuzzo, F, De Toma, A, Friedlaender, A, Metro, G, Pensieri, M, Porzio, G, Ficorella, C, Pinato, D, Cortellini, A, Addeo, A, Banna GL, Tiseo M, Cortinovis D, Facchinetti F, Aerts JGJV, Baldessari C, Giusti R, Bria E, Grossi F, Berardi R, Morabito A, Catino A, Genova C, Mazzoni F, Gelibter A, Rastelli F, Macerelli M, Chiari R, Gori S, Mansueto G, Citarella F, Cantini L, Rijavec E, Bertolini F, Cappuzzo F, De Toma A, Friedlaender A, Metro G, Pensieri MV, Porzio G, Ficorella C, Pinato DJ, Cortellini A, and Addeo A

Abstract

Background: Patients with programmed cell death-ligand 1 (PD-L1) ≥50% metastatic non-small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first-line immunotherapy have heterogeneous clinical assessment and outcomes. Methods: To explore the role of immune-inflammatory surrogates by the validated lung immuno-oncology prognostic score (LIPS) score, including the neutrophil-to-lymphocyte ratio (NLR) and the pretreatment use of steroids, alongside other prognostic variables. A retrospective analysis of 128 patients with PS2 and PD-L1 ≥50% mNSCLC treated between April 2018 and September 2019 with first-line pembrolizumab in a real-world setting was performed. Results: With a median follow-up of 15.3 months, the 1-year overall survival (OS) and median progression-free survival (PFS) were 32.3% (95% CI: 30.9–33.9) and 3.3 months (95% CI: 1.8–4.7), respectively. The NLR, lactate dehydrogenase (LDH) and pretreatment steroids results were the only significant prognostic factors on the univariate analysis and independent prognostic factors by the multivariate analysis on both OS and PFS. The LIPS score, including the NLR and pretreatment steroids, identified 29 (23%) favourable-risk patients, with 0 factors, 1-year OS of 67.6% and median PFS of 8.2 months; 57 (45%) intermediate-risk patients, with 1 factor, 1-year OS 32.1% and median PFS 2.7 months; 42 (33%) poor-risk patients, with both factors, 1-year OS of 10.7% and median PFS of 1.2 months. Conclusions: The assessment of pre-existing imbalance of the host immune response by combined blood and clinical immune-inflammatory markers may represent a way to unravel the heterogeneous outcome and assessment of patients with mNSCLC and poor PS in the immune-oncology setting.

Published
2022

21. Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences

Author

Tabbò, F, Muscarella, L, Gobbini, E, Trombetta, D, Castellana, S, Rigutto, A, Galetta, D, Maiello, E, Martelli, O, Tiseo, M, Scotti, V, Ghilardi, L, Gregorc, V, Sergi, C, Pilotto, S, Del Conte, A, Cappuzzo, F, Cortinovis, D, Osman, G, Bareggi, C, Di Maio, M, Rossi, A, Rossi, G, Bria, E, Volante, M, Scagliotti, G, Graziano, P, Novello, S, Righi, L, Tabbò F, Muscarella LA, Gobbini E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, Righi L, Tabbò, F, Muscarella, L, Gobbini, E, Trombetta, D, Castellana, S, Rigutto, A, Galetta, D, Maiello, E, Martelli, O, Tiseo, M, Scotti, V, Ghilardi, L, Gregorc, V, Sergi, C, Pilotto, S, Del Conte, A, Cappuzzo, F, Cortinovis, D, Osman, G, Bareggi, C, Di Maio, M, Rossi, A, Rossi, G, Bria, E, Volante, M, Scagliotti, G, Graziano, P, Novello, S, Righi, L, Tabbò F, Muscarella LA, Gobbini E, Trombetta D, Castellana S, Rigutto A, Galetta D, Maiello E, Martelli O, Tiseo M, Scotti V, Ghilardi L, Gregorc V, Sergi C, Pilotto S, Del Conte A, Cappuzzo F, Cortinovis D, Osman G, Bareggi C, Di Maio M, Rossi A, Rossi G, Bria E, Volante M, Scagliotti GV, Graziano P, Novello S, and Righi L

Abstract

Introduction: Anaplastic lymphoma kinase (ALK) fusions identify a limited subset of non–small cell lung cancer (NSCLC) patients, whose therapeutic approach have been radically changed in recent years. However, diagnostic procedures and clinical-radiological responses to specific targeted therapies remain heterogeneous and intrinsically resistant or poor responder patients exist. Methods: A total of 290 patients with advanced NSCLC defined as ALK+ by immunohistochemistry (IHC) and/or fluorescent in situ hybridisation (FISH) test and treated with single or sequential multiple ALK inhibitors (ALKi) from 2011 to 2017 have been retrospectively retrieved from a multicentre Italian cancer network database. In 55 patients with enough leftover tumour tissue, specimens were analysed with both targeted and customised next generation sequencing panels. Identified fusion variants have been correlated with clinical outcomes. Results: Of the 55 patients, 24 received crizotinib as first-line therapy, 1 received ceritinib, while 30 received chemotherapy. Most of the patients (64%) received ALKi in sequence. An ALK fusion variant was identified in 73% of the cases, being V3 variant (E6A20) the most frequent, followed by V1 (E13A20) and more rare ones (e.g. E6A19). In three specimens, four new EML4-ALK fusion breakpoints have been reported. Neither fusion variants nor brain metastases were significantly associated with overall survival (OS), while it was predictably longer in patients receiving a sequence of ALKi. The presence of V1 variant was associated with progression-free survival (PFS) improvement when crizotinib was used (p = 0.0073), while it did not affect cumulative PFS to multiple ALKi. Conclusion: Outcomes to sequential ALKi administration were not influenced by fusion variants. Nevertheless, in V1+ patients a prolonged clinical benefit was observed. Fusion variant identification by NGS technology may add relevant information about rare chromosomal events that could be pot

Published
2022

23. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Author

Lee, S, Schulz, C, Prabhash, K, Kowalski, D, Szczesna, A, Han, B, Rittmeyer, A, Talbot, T, Vicente, D, Califano, R, Cortinovis, D, Le, A, Huang, D, Liu, G, Cappuzzo, F, Contreras, J, Reck, M, Palmero, R, Mak, M, Hu, Y, Morris, S, Höglander, E, Connors, M, Biggane, A, Vollan, H, Peters, S, Lee, SM, Han, BH, Le, AT, Huang, DZ, Contreras, JR, Mak, MP, Hu, YY, Biggane, AM, Vollan, HK, Lee, S, Schulz, C, Prabhash, K, Kowalski, D, Szczesna, A, Han, B, Rittmeyer, A, Talbot, T, Vicente, D, Califano, R, Cortinovis, D, Le, A, Huang, D, Liu, G, Cappuzzo, F, Contreras, J, Reck, M, Palmero, R, Mak, M, Hu, Y, Morris, S, Höglander, E, Connors, M, Biggane, A, Vollan, H, Peters, S, Lee, SM, Han, BH, Le, AT, Huang, DZ, Contreras, JR, Mak, MP, Hu, YY, Biggane, AM, and Vollan, HK

Abstract

Background: Despite immunotherapy advancements for patients with advanced or metastatic non-small-cell lung cancer (NSCLC), pivotal first-line trials were limited to patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 and a median age of 65 years or younger. We aimed to compare the efficacy and safety of first-line atezolizumab monotherapy with single-agent chemotherapy in patients ineligible for platinum-based chemotherapy. Methods: This trial was a phase 3, open-label, randomised controlled study conducted at 91 sites in 23 countries across Asia, Europe, North America, and South America. Eligible patients had stage IIIB or IV NSCLC in whom platinum-doublet chemotherapy was deemed unsuitable by the investigator due to an ECOG PS 2 or 3, or alternatively, being 70 years or older with an ECOG PS 0–1 with substantial comorbidities or contraindications for platinum-doublet chemotherapy. Patients were randomised 2:1 by permuted-block randomisation (block size of six) to receive 1200 mg of atezolizumab given intravenously every 3 weeks or single-agent chemotherapy (vinorelbine [oral or intravenous] or gemcitabine [intravenous]; dosing per local label) at 3-weekly or 4-weekly cycles. The primary endpoint was overall survival assessed in the intention-to-treat population. Safety analyses were conducted in the safety-evaluable population, which included all randomised patients who received any amount of atezolizumab or chemotherapy. This trial is registered with ClinicalTrials.gov, NCT03191786. Findings: Between Sept 11, 2017, and Sept 23, 2019, 453 patients were enrolled and randomised to receive atezolizumab (n=302) or chemotherapy (n=151). Atezolizumab improved overall survival compared with chemotherapy (median overall survival 10·3 months [95% CI 9·4–11·9] vs 9·2 months [5·9–11·2]; stratified hazard ratio 0·78 [0·63–0·97], p=0·028), with a 2-year survival rate of 24% (95% CI 19·3–29·4) with atezolizumab compared with 12% (6·7–18·0) with

Published
2023

24. PP01.54 ImmunoBlood: A Prospective Study Evaluating the Development of Anti-Checkpoint Inhibitor Antibodies in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy

Author

Orciuolo, C., primary, Sorrentino, R., additional, Colarusso, C., additional, Ceddia, S., additional, Minuti, G., additional, Conti, L., additional, Mandoj, C., additional, Carpano, S., additional, Canali, L., additional, Fucci, C., additional, Brandi, M., additional, Fusco, F., additional, Giammaruco, M., additional, Resuli, B., additional, Landi, L., additional, and Cappuzzo, F., additional

Published
2023
Full Text
View/download PDF

25. 70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial

Author

Botticelli, A., primary, Scagnoli, S., additional, Conte, P.F., additional, Cremolini, C., additional, Ascierto, P.A., additional, Aglietta, M., additional, Mazzuca, F., additional, Capoluongo, E., additional, Malapelle, U., additional, Nuti, M., additional, D'Amati, G., additional, Cerbelli, B., additional, Pruneri, G., additional, Giannini, G., additional, Cappuzzo, F., additional, Biffoni, M., additional, Blandino, G., additional, Cognetti, F., additional, Curigliano, G., additional, and Marchetti, P., additional

Published
2023
Full Text
View/download PDF

26. Low risk of hyperprogression with first-line chemoimmunotherapy for advanced non-small cell lung cancer: pooled analysis of 7 clinical trials

Author

Li, L.X. (Lee X.), Cappuzzo, F. (Federico), Matos, I. (Ignacio), Socinski, M.A. (Mark A.), Hopkins, A.M. (Ashley M.), and Sorich, M.J. (Michael J.)

Subjects
Hyperprogression, Hyperprogressive disease, Non-small cell lung cancer, Immune checkpoint inhibitor, Chemoimmunotherapy
Abstract

Background Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer (NSCLC), and provides insights into hyperprogression risk with contemporary first-line ICI treatment. Methods Hyperprogression was identified using Response Evaluation Criteria in Solid Tumours (RECIST)-based criteria in a dataset of pooled individual-participant level data from BIRCH, FIR, IMpower130, IMpower131, IMpower150, OAK, and POPLAR trials. Odds ratios were computed to compare hyperprogression risks between groups. Landmark Cox proportional-hazard regression was used to evaluate the association between hyperprogression and progression-free survival/overall survival. Secondarily, putative risk factors for hyperprogression among second- or later-line atezolizumab-treated patients were evaluated using univariate logistic regression models. Results Of the included 4644 patients, 119 of the atezolizumab-treated patients (n = 3129) experienced hyperprogression. Hyperprogression risk was markedly lower with first-line atezolizumab-either chemoimmunotherapy or monotherapy-compared to second/later-line atezolizumab monotherapy (0.7% vs. 8.8%, OR = 0.07, 95% CI, 0.04-0.13). Further, there was no statistically significant difference in hyperprogression risk with first-line atezolizumab-chemoimmunotherapy versus chemotherapy alone (0.6% vs. 1.0%, OR = 0.55, 95% CI, 0.22-1.36). Sensitivity analyses using an extended RECIST-based criteria including early death supported these findings. Hyperprogression was associated with worsened overall survival (HR = 3.4, 95% CI, 2.7-4.2, P < .001); elevated neutrophil-to-lymphocyte ratio was the strongest risk factor for hyperprogression (C-statistic = 0.62, P < .001). Conclusions This study presents first evidence for a markedly lower hyperprogression risk in advanced NSCLC patients treated with first-line ICI, particularly with chemoimmunotherapy, as compared to second- or later-line ICI treatment. This study evaluated hyperprogression risk with the use of immune checkpoint inhibitor (ICI) in the first-, second-, or later-line treatment of advanced non-small cell lung cancer, providing insight into hyperprogression risk with contemporary first-line ICI treatment.

Published
2023

27. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial

Author

Del Mastro, Lucia, primary, Poggio, Francesca, additional, Blondeaux, Eva, additional, De Placido, Sabino, additional, Giuliano, Mario, additional, Forestieri, Valeria, additional, De Laurentiis, Michelino, additional, Gravina, Adriano, additional, Bisagni, Giancarlo, additional, Rimanti, Anita, additional, Turletti, Anna, additional, Nisticò, Cecilia, additional, Vaccaro, Angela, additional, Cognetti, Francesco, additional, Fabi, Alessandra, additional, Gasparro, Simona, additional, Garrone, Ornella, additional, Alicicco, Maria Grazia, additional, Urracci, Ylenia, additional, Mansutti, Mauro, additional, Poletti, Paola, additional, Correale, Pierpaolo, additional, Bighin, Claudia, additional, Puglisi, Fabio, additional, Montemurro, Filippo, additional, Colantuoni, Giuseppe, additional, Lambertini, Matteo, additional, Boni, Luca, additional, Venturini, M, additional, Abate, A, additional, Pastorino, S, additional, Canavese, G, additional, Vecchio, C, additional, Guenzi, M, additional, Lambertini, M, additional, Levaggi, A, additional, Giraudi, S, additional, Accortanzo, V, additional, Floris, C.A., additional, Aitini, E, additional, Fornari, G, additional, Miraglia, S, additional, Buonfanti, G, additional, Cherchi, M.C., additional, Petrelli, F, additional, Vaccaro, A, additional, Magnolfi, E, additional, Contu, A, additional, Labianca, R, additional, Parisi, A, additional, Basurto, C, additional, Cappuzzo, F, additional, Merlano, M, additional, Russo, S, additional, Mansutti, M, additional, Poletto, E, additional, Nardi, M, additional, Grasso, D, additional, Fontana, A, additional, Isa, L, additional, Comandè, M, additional, Cavanna, L, additional, Iacobelli, S, additional, Milani, S, additional, Mustacchi, G, additional, Venturini, S, additional, Scinto, A.F., additional, Sarobba, M.G., additional, Pugliese, P, additional, Bernardo, A, additional, Pavese, I, additional, Coccaro, M, additional, Massidda, B, additional, Ionta, M.T., additional, Nuzzo, A, additional, Laudadio, L, additional, Chiantera, V, additional, Dottori, R, additional, Barduagni, M, additional, Castiglione, F, additional, Ciardiello, F, additional, Tinessa, V, additional, Ficorella, A, additional, Moscetti, L, additional, Vallini, I, additional, Giardina, G, additional, Silva, R, additional, Montedoro, M, additional, Seles, E, additional, Morano, F, additional, Cruciani, G, additional, Adamo, V, additional, Pancotti, A, additional, Palmisani, V, additional, Ruggeri, A, additional, Cammilluzzi, E, additional, Carrozza, F, additional, D'Aprile, M, additional, Brunetti, M, additional, Gallotti, P, additional, Chiesa, E, additional, Testore, F, additional, D'Arco, A, additional, Ferro, A, additional, Jirillo, A, additional, Pezzoli, M, additional, Scambia, G, additional, Iacono, C, additional, Masullo, P, additional, Tomasello, G, additional, Gandini, G, additional, Zoboli, A, additional, Bottero, C, additional, Cazzaniga, M, additional, Genua, G, additional, Palazzo, S, additional, D'Amico, M, additional, and Perrone, D, additional

Published
2022
Full Text
View/download PDF

29. Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer

Author

Stasi I and Cappuzzo F

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Irene Stasi, Federico Cappuzzo Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Bavituximab is a an unconjugated, chimeric immunoglobulin G1 (IgG1) monoclonal antibody directed against the phosphatidylserine (PS) expressed on tumor endothelium, with a specific mechanism of action. PS is an anionic membrane phospholipid, physiologically restricted to the internal membrane leaflet; various pathophysiologic processes cause the exposure of PS on the external membrane leaflet. Bavituximab, once bound, starts up host effector activities, such as antibody dependent cellular cytotoxicity, causing vessel destruction and enhancing antitumor immunity. Phase I clinical trials of bavituximab administered as monotherapy or in combination with other chemotherapeutic agents in adults with pretreated solid tumors have been accomplished, indicating that bavituximab can be safely dispensed weekly, with a recommended dose of 1 and 3 mg/kg. A Phase II randomized, placebo-controlled trial of bavituximab plus docetaxel, in the second-line therapy setting of locally advanced or metastatic non-small-cell lung cancer, has been conducted and recently presented, suggesting a clinical benefit of the combination, with an overall response rate of 17% and median overall survival of more than 11 months. A Phase III trial is currently ongoing. Bavituximab has been studied in combination with platinum-based doublets with promising results. In the present paper we summarize the preclinical development and clinical experience with bavituximab in non-small-cell lung cancer. Keywords: bavituximab, NSCLC, targeted therapy, vascular disrupting agent, vascular targeting agent

Published
2014

31. 1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial

Author

Cappuzzo, F., primary, Delmonte, A., additional, Landi, L., additional, Andrikou, K., additional, Dal Maso, A., additional, Minuti, G., additional, Lee, C., additional, Wang, X., additional, Papi, M., additional, Metro, G., additional, Attili, I., additional, Piantedosi, F.V., additional, Pilotto, S., additional, Gori, S., additional, Rossi, G., additional, Buglioni, S., additional, Giannarelli, D., additional, and Bonanno, L., additional

Published
2022
Full Text
View/download PDF

32. EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial

Author

Delmonte, A., primary, Bonanno, L., additional, Landi, L., additional, Andrikou, K., additional, Dal Maso, A., additional, Minuti, G., additional, Papi, M., additional, Metro, G., additional, Attili, I., additional, Piantedosi, F., additional, Pilotto, S., additional, Gori, S., additional, Rossi, G., additional, Buglioni, S., additional, Giannarelli, D., additional, and Cappuzzo, F., additional

Published
2022
Full Text
View/download PDF

33. 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial

Author

Botticelli, A., primary, Scagnoli, S., additional, Conte, P.F., additional, Cremolini, C., additional, Ascierto, P.A., additional, Cappuzzo, F., additional, Aglietta, M., additional, Mazzuca, F., additional, Capoluongo, E., additional, Blandino, G., additional, Malapelle, U., additional, Nuti, M., additional, D'Amati, G., additional, Cerbelli, B., additional, Pruneri, G., additional, Biffoni, M., additional, Giannini, G., additional, Cognetti, F., additional, Curigliano, G., additional, and Marchetti, P., additional

Published
2022
Full Text
View/download PDF

34. EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base

Author

Malapelle, U., primary, Pepe, F., additional, Pisapia, P., additional, Righi, L., additional, Listì, A., additional, Reale, M.L., additional, Passiglia, F., additional, Tiseo, M., additional, Genova, C., additional, Galetta, D., additional, Cortinovis, D., additional, Pilotto, S., additional, Migliorino, M.R., additional, Parra, H. Soto, additional, Cappuzzo, F., additional, Novello, S., additional, and Troncone, G., additional

Published
2022
Full Text
View/download PDF

35. P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial

Author

Landi, L., primary, Tiseo, M., additional, Heukamp, L.C., additional, Menon, R., additional, de Marinis, F., additional, Minuti, G., additional, Cortinovis, D.L., additional, Delmonte, A., additional, Galetta, D., additional, Bertrand, M., additional, Zacher, A., additional, Gridelli, C., additional, Jacobs, F., additional, Chiari, R., additional, Verusio, C., additional, Giannarelli, D., additional, Crinò, L., additional, and Cappuzzo, F., additional

Published
2022
Full Text
View/download PDF

36. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial

Author

Garcia Campelo, M.R., primary, Felip, E., additional, Besse, B., additional, Cobo Dols, M., additional, Quoix, E., additional, Madroszyk Flandin, A-C., additional, Cappuzzo, F., additional, Denis, F., additional, Hilgers, W., additional, Romano, G., additional, Debieuvre, D., additional, Galetta, D., additional, Baldini, E., additional, Viteri Ramirez, S., additional, Duc Phan, M., additional, Schuette, W., additional, Zer, A., additional, Vasseur, B., additional, Dziadziuszko, R., additional, and Giaccone, G., additional

Published
2022
Full Text
View/download PDF

37. EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial

Author

Cappuzzo, F., primary, Chiari, R., additional, Tiseo, M., additional, Minotti, V., additional, De Marinis, F., additional, Delmonte, A., additional, Bungaro, M., additional, Cortinovis, D.L., additional, Galetta, D., additional, Bonanno, L., additional, Chella, A., additional, Gridelli, C., additional, Morabito, A., additional, Grossi, F., additional, Bria, E., additional, Giannarelli, D., additional, Fontanini, G., additional, Borra, G., additional, Gori, S., additional, Mazzoni, F., additional, Pilotto, S., additional, and Landi, L., additional

Published
2022
Full Text
View/download PDF

38. 1024P Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial

Author

Buyse, M.E., primary, Montestruc, F., additional, Chiem, J-C., additional, Deltuvaite-Thomas, V., additional, Salvaggio, S., additional, Garcia Campelo, M.R., additional, Cobo Dols, M., additional, Quoix, E., additional, Madroszyk Flandin, A-C., additional, Cappuzzo, F., additional, Romano, G., additional, Viteri Ramirez, S., additional, Schuette, W., additional, Zer, A., additional, Comis, S., additional, Vasseur, B., additional, Dziadziuszko, R., additional, Giaccone, G., additional, Besse, B., additional, and Felip, E., additional

Published
2022
Full Text
View/download PDF

39. 1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC)

Author

Meisel, A., primary, Mark, M.T., additional, Haider, A., additional, Holer, L., additional, Hayoz, S., additional, Gebhard, C., additional, Bengs, S., additional, Treyer, V., additional, Rothschild, S.I., additional, Hochmair, M.J., additional, Gandara, D.R., additional, Cappuzzo, F., additional, Reck, M., additional, Stenner-Liewen, F., additional, and von Moos, R.A.F., additional

Published
2022
Full Text
View/download PDF

40. 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)

Author

Gadgeel, S.M., primary, Gainor, J., additional, Cappuzzo, F., additional, Garralda, E., additional, Lee, D.H., additional, Mazieres, J., additional, Kim, D-W., additional, Zhu, V., additional, Lopes, G., additional, Miller, S., additional, Nowicka, M., additional, Trinh, H., additional, Arndorfer, S.M., additional, Rahman, A., additional, Noe, J., additional, Zhang, Q., additional, and Subbiah, V., additional

Published
2022
Full Text
View/download PDF

41. LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Author

Lee, S.M., primary, Schulz, C., additional, Prabhash, K., additional, Han, B., additional, Szczesna, A., additional, Cortinovis, D.L., additional, Rittmeyer, A., additional, Baz, D. Vicente, additional, Califano, R., additional, Anh, L. Tuan, additional, Liu, G., additional, Cappuzzo, F., additional, Contreras, J.G. Reyes, additional, Reck, M., additional, Hu, Y., additional, Morris, S., additional, Hoeglander, E.K., additional, Connors, M., additional, Vollan, H.K.M., additional, and Peters, S., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results